Dermatology

Top Story

Evidence lacking for comparative effectiveness, safety of skin cancer treatments

Evidence lacking for comparative effectiveness, safety of skin cancer treatments
September 17, 2018
In the JournalsPerspective

Infliximab biosimilar 'only moderately' less costly vs. biologic under Medicare Part D

September 4, 2018
Under Medicare Part D drug benefits, the biosimilar infliximab-dyyb was only 18% less expensive than the infliximab reference product, exceeding $14,000 annually…
FDA News

FDA approves Altreno for acne treatment in kids, adults

August 24, 2018
The FDA has approved a new drug application for Altreno, a topical treatment for acne vulgaris produced by Ortho Dermatologics. This lotion (tretinoin 0.05%) is…
Meeting News

Psoriasis with less than 10% body surface area can still be severe

August 24, 2018
FORT WORTH, Texas — Patients with psoriasis affecting less than 10% body surface area can be considered severe cases, especially among those with psoriatic…
More Headlines »
CME CNE CPE CDR CE

Management Implications of Non-HDL Lipids and Inflammation in CAD

This educational activity is supported by an educational grant from Amarin Pharma Inc.

This 1-hour, highly interactive CME-certified symposium will feature a faculty of 5 leading international experts who…
More »
GI Bookshelf

Chapter 36: Management of Acute and Chronic Pouchitis

From Ulcerative Colitis: The Complete Guide to Medical Management
More »
Resource Centers
Video
Meeting News

VIDEO: Treating psoriasis and melasma in skin of color

March 9, 2017
More »